The HSD17B13 association is consistent with a recent study reporting that a loss-of-function variant associated with decreased levels of ALT and aspartate aminotransferase (AST) and reduced the risk of liver disease and progression from NAFLD to NASH [22]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.